Predicting the toxicity of weekly docetaxel in advanced cancer

Clinical Pharmacokinetics

Volumn 45, Issue 6, 2006, Pages 611-622

  Charles, Kellie A ^a   Rivory, Laurent P ^a,b   Stockler, Martin R ^b,c   Beale, Philip ^b   Beith, Jane ^b   Boyer, Michael ^b   Clarke, Stephen J ^b,d  

^a University of Sydney   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DOCETAXEL; OROSOMUCOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 33745895305     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645060-00004     Document Type: Article

References (41)

1. Bruno R, Vivler N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinetic Biopharm 1996 Apr; 24 (2): 153-72
2. Yamamoto N, Tamura T, Kamiya Y, et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000 Jun; 18 (11): 2301-8
3. Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000 Apr; 6 (4): 1255-8
4. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000 May; 36 (8): 1016-25
5. Couteau C, Chouaki N, Leyvraz S, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999 Oct; 81 (3): 457-62
6. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998 Jan; 16 (1): 187-96
7. Greco FA. Docetaxel (taxotere) administered in weekly schedules. Semin Oncol 1999 Jun; 26 (3 Suppl 11): 28-31
8. Hainsworth JD, Burris III HA, Greco FA. Weekly administration of docetaxel (taxotere): summary of clinical data. Semin Oncol 1999 Jun; 26 (3 Suppl 10): 19-24
9. Loffler TM. Is there a place for 'dose-dense' weekly schedules of the taxoids? Semin Oncol 1998 Oct; 25 (5 Suppl. 12): 32-4
10. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000 Mar; 18 (6): 1212-9
11. Hainsworth JD, Burris III HA, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001 Jun; 28 (3 Suppl. 9): 21-5
12. Gusmao AB, Bines J, Martins RG, et al. Primary chemotherapy with weekly docetaxel (Taxotere) in poor prognosis advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21: 42b
13. Gervais R, Ducolone AMD, Breton J-L, et al. Mult-centre, randomised, Phase II trial of docetaxel (Taxotere) 75mg.m2 q3w versus 40mg/m2 weekly in patients with pretreated non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21: 310a
14. Sedky L, Saad El-Dine I, Hashem B, et al. Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study [abstract]. Proc Am Soc Clin Oncol 2002; 21: 50b
15. Slaviero KA, Clarke SJ, McLachlan AJ, et al. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004 Jan; 57 (1): 44-53
16. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995 Apr 15; 75 (8): 2077-82
17. Nozoe T, Matsumata T, Kitamura M, et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998 Oct; 176 (4): 335-8
18. Mahmoud FA, Rivera N. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002 May; 4 (3): 250-5
19. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999 Mar-Apr; 19 (2B): 1427-32
20. Extermann M. Comprehensive geriatric assessment basics for the cancer professional. J Oncol Manag 2003 Mar-Apr; 12 (2): 13-7
21. Slaviero KA, Read JA, Clarke SJ, et al. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 2003; 46 (2): 148-57
22. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: the mini nutritional assessment as part of the geriatric evaluation. Nutr Rev 1996 Jan; 54 (1 Pt 2): S59-65
23. Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000 Sep; 6 (9): 3480-5
24. Bruno R, Olivares R, Berille J, et al. alpha-1-acid glycoprotein as an independent predictor for treatment effect and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003 Mar; 9 (3): 1077-82
25. Graf W, Pahlman L, Bergstrom R, et al. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994 Sep; 70 (3): 559-63
26. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000 Jul 29; 356 (9227): 373-8
27. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003 Feb 20; 103 (5): 642-6
28. Engelken FJ, Bettschart V, Rahman MQ, et al. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 2003 May; 29 (4): 368-73
29. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003 Feb; 90 (2): 215-9
30. Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002 Jul 29; 87 (3): 264-7
31. Thompson DK, Haddow JE, Smith DE, et al. Elevated serum acute phase protein levels as predictors of disseminated disease. Cancer 1983 Jun 1; 51 (11): 2100-4
32. Ardestani SK, Inserra P, Solkoff D, et al. The role of cytokines and chemokines on tumor progression: a review. Cancer Detect Prev 1999; 23 (3): 215-25
33. Balkwill F. Cytokine amplification and inhibition of immune and inflammatory responses. J Viral Hepat 1997; 4 Suppl. 2: 6-15
34. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992 Jan; 62 (1 Pt 2): S60-5
35. Kulmatycki KM, Jamali F. Therapeutic relevance of altered cytokine expression. Cytokine 2001 Apr 7; 14 (1): 1-10
36. Deeg HJ, Seidel K, Bruemmer B, et al. Impact of weight loss on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 1995 Mar; 15 (3): 461-8
37. Andreyev HJ, Norman AR, Oates J, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998 Mar; 34 (4): 503-9
38. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980 Oct; 69 (4): 491-7
39. Thoresen L, Fjeldstad I, Krogstad K, et al. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med 2002 Jan; 16 (1): 33-42
40. Zulian GB, Gold G, Herrmann F, et al. Mini nutritional assessment and cancer. Nestle Nutr Workshop Ser Clin Perform Programme 1999; 1: 93-8, 99-100
41. Persson C, Glimelius B. The relevance of weight loss for survival and quality of life with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 2002 Nov-Dec; 22 (6B): 3661-8